Finance
Results: 33745-33756 of 43926

AXIS Capital Reports First Quarter Net Income Available to Common Shareholders of $388 Million, or $4.53 Per Diluted Common Share and Operating Income of $220 Million, or $2.57 Per Diluted Common Share

Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance









